1.Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma.
Longyun WANG ; Qingsong TU ; Weibing ZHOU ; Rongrong ZHOU
Journal of Central South University(Medical Sciences) 2011;36(11):1106-1110
OBJECTIVE:
To study the efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide (TMZ) for gliomas.
METHODS:
A total of 78 patients with pathologically confirmed glioma ( from September 2005 to March 2007) were postoperatively divided into 3 groups: a chemotherapy group (n=24), a radiotherapy group (n=25), and a comprehensive therapy group(n=29). The patients received temozolomide alone,3-dimensional conformal radiotherapy alone,3-dimensional conformal radiotherapy combined with temozolomide in the chemotherapy group,the radiotherapy group and the comprehensive therapy group respectively. The survival rate, progression-free survival, overall survival time and adverse reactions were observed.
RESULTS:
The 3-year survival rate in the comprehensive therapy group was significantly higher than that in the other two groups. The 3-year survival rates were 20.83%, 20.00%, and 41.38% in the chemotherapy group, the radiotherapy group and the comprehensive therapy group respectively. The progression-free survival time was 17.68,17.94, and 23.29 months and the average overall survival time was 20.28, 21.54, and 25.75 months in the chemotherapy group, the radiotherapy group and the comprehensive therapy group, respectively.The adverse reactions were mild and tolerable.
CONCLUSION
Three-dimensional conformal radiotherapy combined with temozolomide is more effective for gliomas than the simple 3-dimensional conformal radiotherapy and the temozolomide chemotherapy alone.
Adult
;
Aged
;
Antineoplastic Agents, Alkylating
;
therapeutic use
;
Brain Neoplasms
;
drug therapy
;
radiotherapy
;
surgery
;
Combined Modality Therapy
;
adverse effects
;
Dacarbazine
;
analogs & derivatives
;
therapeutic use
;
Female
;
Glioma
;
drug therapy
;
radiotherapy
;
surgery
;
Humans
;
Male
;
Middle Aged
;
Postoperative Period
;
Radiotherapy, Conformal
;
methods
;
Retrospective Studies
;
Survival Analysis
;
Temozolomide
2.Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas.
Seung Ho YANG ; Moon Kyu KIM ; Tae Kyu LEE ; Kwan Sung LEE ; Sin Soo JEUN ; Chun Kun PARK ; Joon Ki KANG ; Moon Chan KIM ; Yong Kil HONG
Journal of Korean Medical Science 2006;21(4):739-744
Numerous studies have demonstrated the clinical activity of temozolomide, a second-generation alkylating agent, against malignant brain tumors, however, its activity has not been reported in an Asian population. This study analyzed the efficacy and toxicity of temozolomide in 25 adult patients with recurrent or progressive malignant gliomas after surgery and standard radiation therapy with or without chemotherapy, enrolled in our institution since July 2000. Sixteen patients had glioblastoma multiforme (GBM), six with anaplastic astrocytoma, and three with anaplastic oligodendroglioma. Of the 25 patients, 3 (12%) achieved a complete response (CR), 8 (32%) achieved a partial response (PR), 6 (24%) had stable disease (SD), and 8 (32%) had progressive disease (PD). Two patients achieved a CR, 4 patients achieved a PR, 3 patients had SD and 7 patients had PD in GBM, and 1 patient achieved a CR, 4 patients achieved a PR, 3 patients had SD, 1 patient had PD in the non-GBM patients. Median progression free survival was 8 weeks in GBM and 22 weeks in the non-GBM patients. The median overall survival of each group was 17 weeks and 28 weeks. Temozolomide demonstrated moderate activity in recurrent and progressive malignant gliomas without serious toxicity.
Vomiting/chemically induced
;
Treatment Outcome
;
Survival Analysis
;
Neoplasm Recurrence, Local
;
Nausea/chemically induced
;
Middle Aged
;
Male
;
Magnetic Resonance Imaging
;
Liver Diseases/chemically induced
;
Leukopenia/chemically induced
;
Humans
;
Glioma/*drug therapy/radiotherapy/surgery
;
Female
;
Drug Administration Schedule
;
Dacarbazine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use
;
Combined Modality Therapy
;
Brain Neoplasms/*drug therapy/radiotherapy/surgery
;
Brain/drug effects/pathology
;
Antineoplastic Agents, Alkylating/administration & dosage/adverse effects/therapeutic use
;
Adult
;
Adolescent
;
Administration, Oral